Sector News

Solvay launches 1.5 bln euro rights issue for Cytec buy

December 3, 2015
Life sciences

(Reuters) – Solvay SA launched a share issue to existing shareholders on Thursday to complete funding for the Belgian chemicals group’s $5.5 billion purchase of Cytec Industries Inc.

Existing shareholders will receive the right to buy one new share at 70.83 euros for every four existing shares. Solvay shares closed on Wednesday at 105.80 euros.

The rights subscription period will last until Dec. 15. with settlement on or around Dec. 21.

Solvay said it expected to close its acquisition of Cytec on Dec. 9 after securing conditional antitrust clearance from the European Commission on Wednesday.

Solvay shareholder Solvac has committed to exercise in full its rights and thereby maintain its 30.20 percent stake.

Also on Thursday it announced a two-for-five rights issue of up to 452 million euros at an issue price of 74 euros.

In buying Cytec, Solvay will gain a leader in lightweight composite materials for which there is increasing demand from the aerospace and automotive sectors as they seek to reduce carbon dioxide emissions.

It will also add to Solvay’s existing formulations to maximise the amount of ore extracted in mining.

Solvay sold $1.6 billion of bonds Tuesday after a 2.25 billion euro bond and 1.0 billion hybrid bond issue last week. (Reporting by Philip Blenkinsop; editing by Jason Neely)

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach